Highlights:
- CABANA finds reduced AF and better quality of life after ablation but no reduction in mortality
- ELIMINATE-AF shows low thromboembolic and bleeding events with edoxaban
- Profile: Charles Antzelevitch
- Victor Sanfins discusses his clinical experience with Biotronik’s Acticor/Rivacor ICDs and CRT-Ds
- Andrea Natale writes about high-power short-duration AF ablation
